Article
Cholesteryl Ester as a Prognostic Biomarker In IDH-wildtype Glioblastoma
2026-05-08
Abstract excerpt
Current treatment of IDH-wildtype glioblastoma (GBM) relies on the first-line chemotherapy-temozolomide. Although MGMT methylation is routinely conducted to predict chemosensitivity, its efficacy is often compromised. Thus, there is an urgent need to discover more accurate prognostic biomarkers. Cholesteryl ester (CE) has been recently recognized as a key feature of GBM, however, its role in GBM prognosis remains...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 19378e80-c335-54ad-8fdb-7d6f73f22b08
- DOI
- 10.64898/2026.05.05.722825
